Virology
NanoViricides Proposes NV-387 for Bundibugyo Ebola Outbreak Amid Lack of Approved Treatments
NanoViricides highlights its broad-spectrum antiviral NV-387 as a potential treatment for the Bundibugyo Ebola outbreak in Africa, where no approved vaccines or therapies exist, leveraging its host-targeted mechanism and oral formulation for easier deployment.
GeoVax CEO David Dodd to Discuss MVA-Based Vaccine Platforms for Broader Infectious Disease Preparedness in Tribe Public Webinar
GeoVax Labs CEO David Dodd will participate in a Tribe Public webinar on May 28, 2026, to discuss the need for platform-based vaccine technologies to address multiple viral threats like Ebola, Marburg, mpox, and hantavirus, emphasizing the limitations of single-threat preparedness.
GeoVax Highlights MVA Platform's Potential Amid Bundibugyo Ebola Outbreak
GeoVax Labs comments on the WHO-declared PHEIC for Bundibugyo Ebola, emphasizing the need for flexible vaccine platforms like its MVA-based technology to address emerging viral threats.
NanoViricides Highlights Broad-Spectrum Antiviral NV-387 Amid Ebola Outbreak
NanoViricides underscores the potential of its oral drug candidate NV-387 as a pandemic preparedness tool amid the ongoing Bundibugyo Ebola outbreak in the Democratic Republic of Congo and Uganda.
NanoViricides Raises $2 Million in Registered Direct Offering to Advance Broad-Spectrum Antiviral Drug
NanoViricides announced a $2 million registered direct offering with a single institutional investor, aiming to fund development of its broad-spectrum antiviral NV-387, which targets multiple viruses including COVID-19, influenza, and RSV.
NanoViricides Advances Broad-Spectrum Antiviral NV-387 Toward Phase II Trials for MPox in DRC
NanoViricides' quarterly report details progress with NV-387, including regulatory approval for Phase II MPox trials in the DRC and FDA orphan drug designation for measles, highlighting its broad-spectrum antiviral strategy.
NanoViricides Highlights Broad-Spectrum Antiviral Candidate After Andes Hantavirus Incident on Cruise Ship
NanoViricides points to its clinical-stage antiviral candidate NV-387 as a potential broad-spectrum therapeutic following an Andes hantavirus incident aboard a cruise ship, underscoring the need for versatile antiviral treatments.
NanoViricides to Present at D. Boral Capital Global Conference Amid Progress on Broad-Spectrum Antiviral NV-387
NanoViricides will participate in the D. Boral Capital Global Conference, highlighting its clinical-stage antiviral drug NV-387 and its potential to treat multiple viral infections including RSV, COVID, and Monkeypox.
NanoViricides Gains FDA Orphan Drug Designation for Measles Drug NV-387 Amid Global Outbreaks
NanoViricides received FDA Orphan Drug Designation for its broad-spectrum antiviral NV-387 to treat measles, offering incentives and supporting regulatory advancement as global cases rise.
NanoViricides Highlights NV-387 as Potential Measles Treatment Amid Global Outbreak Concerns
NanoViricides announced its antiviral drug candidate NV-387 may address the growing global measles outbreak, potentially complementing vaccination efforts by reducing transmission and treating infected patients.
NanoViricides Secures $6 Million in Funding to Advance Antiviral Drug Development
NanoViricides has raised $6 million through a registered direct offering and concurrent private placement, providing crucial capital to advance its broad-spectrum antiviral drug candidates including NV-387 for respiratory infections and NV-HHV-1 for shingles treatment.
NanoViricides Receives Regulatory Approval for Phase II MPox Trial in Democratic Republic of Congo
NanoViricides has received regulatory approval to begin Phase II clinical trials for its broad-spectrum antiviral drug NV-387 to treat MPox in the Democratic Republic of Congo, representing a potential breakthrough in antiviral therapy.
NanoViricides Sets 2025 Annual Shareholders Meeting Amid Clinical Development Push
NanoViricides announced its 2025 shareholders meeting while advancing multiple antiviral drug candidates including NV-387 for respiratory infections and NV-HHV-1 for shingles treatment.
NanoViricides Reports Promising Anti-Measles Results for Broad-Spectrum Antiviral Candidate NV-387
NanoViricides' experimental drug NV-387 demonstrates strong efficacy against Measles in preclinical studies, potentially addressing the critical gap in approved treatments for the resurgent viral disease.
NanoViricides to Present Antiviral Pipeline Updates at PODD 2025 Conference
NanoViricides will showcase its broad-spectrum antiviral drug platform at the upcoming PODD 2025 conference, highlighting progress toward Phase II trials for its lead candidate NV-387 targeting multiple respiratory viruses and MPox.
Erica Ollmann Saphire Honored with 2025 San Diego Genius Award for Pioneering Immunology Research
Dr. Erica Ollmann Saphire, a leading figure in immunology research, is set to receive the 2025 San Diego Genius Award for her groundbreaking work on viral infections and immune system responses, highlighting the intersection of science and community enrichment.
GeoVax Advocates for MVA-Based Vaccines Following HHS mRNA Vaccine Rollback
GeoVax Labs highlights the advantages of its MVA-based multi-antigen vaccine, GEO-CM04S1, as a solution to the limitations of mRNA vaccines identified by the HHS, emphasizing broader and more durable protection against COVID-19 and other viruses.
NanoViricides' NV-387 Emerges as Potential Breakthrough in Combatting Measles Outbreaks
NanoViricides Inc. announces its drug candidate NV-387 could significantly impact the treatment of measles, addressing a critical gap in antiviral medications amid rising global outbreaks.
NanoViricides' NV-387 Shows Promise as Broad-Spectrum Antiviral with Strategic Pandemic Preparedness Value
NanoViricides, Inc. highlights NV-387's broad antiviral potential and its strategic importance for pandemic preparedness, with plans for a Phase II trial targeting MPox.
Modified Herpes Virus Shows Promise in Treating Advanced Melanoma
A recent study indicates that a genetically altered herpes virus could offer a new treatment avenue for advanced melanoma, highlighting the potential of oncolytic viruses in cancer therapy.
NanoViricides Advances MPox Treatment Amid WHO's Extended Health Emergency
NanoViricides, Inc. progresses with NV-387, a broad-spectrum antiviral drug, as the WHO extends the MPox global health emergency, highlighting the drug's potential to fill gaps in current treatments.
Calidi Biotherapeutics Featured in NetworkNewsWire Spotlight on Genetic Medicines
Calidi Biotherapeutics' innovative approach to treating hard-to-treat cancers with engineered viruses is highlighted in a NetworkNewsWire editorial, showcasing its potential to transform cancer treatment and address autoimmune disorders.
Calidi Biotherapeutics' Genetic Medicine Platform Highlighted for Potential Cancer Breakthrough
Calidi Biotherapeutics Inc. (NYSE American: CLDI) has been featured in an editorial for its precision genetic medicine platform, which could revolutionize cancer treatment by targeting tumors with engineered viruses.
NanoViricides' NV-387 Emerges as a Promising Broad-Spectrum Antiviral Against COVID-19 and Bird Flu
NanoViricides, Inc. highlights NV-387, its broad-spectrum antiviral candidate, as a potential game-changer in combating emerging COVID-19 variants and Bird Flu strains, showcasing its superior performance in animal models and readiness for cGMP manufacturing.
Legal Notice Calls for Investigation into COVID-19 Origins and Vaccine Technologies
Dr. Leonard G. Horowitz has issued a legal notice urging a thorough investigation into the origins of COVID-19 and the technologies used in vaccine development, highlighting concerns over potential health risks and the need for transparency.
GeoVax's Multi-Antigen COVID-19 Vaccine Shows Promise Against Variants
GeoVax Labs, Inc. reports preclinical success of its multi-antigen COVID-19 vaccines, GEO-CM04S1 and GEO-CM02, in providing durable, cross-reactive immunity against SARS-CoV-2 variants, including Omicron XBB.1.5, highlighting the potential for broader protection without the need for frequent updates.
GeoVax to Present COVID-19 Vaccine Breakthroughs at Keystone Symposia
GeoVax Labs, Inc. will showcase data from two key studies at the Keystone Symposia, highlighting the cross-reactivity and broad-spectrum immunity of its COVID-19 vaccine candidates, marking a significant step forward in the fight against evolving SARS-CoV-2 variants.
NanoViricides Highlights Potential Antiviral Solution Amid Changing COVID Booster Recommendations
NanoViricides' President Dr. Anil Diwan comments on the FDA's updated COVID-19 booster policy, emphasizing the need for alternative antiviral treatments and positioning the company's NV-387 drug candidate as a potential solution for respiratory viral infections.
New Research Illuminates Potential Link Between Epstein-Barr Virus and Multiple Sclerosis
Scientific research is uncovering a complex relationship between Epstein-Barr virus exposure and Multiple Sclerosis, highlighting the potential for deeper understanding of disease mechanisms and future treatment strategies.
NanoViricides Advances Promising Antiviral Drug Against Measles and MPox
NanoViricides is developing NV-387, a potential breakthrough treatment for Measles and MPox amid rising global case counts and limited medical interventions. The drug represents a critical advancement in addressing urgent infectious disease challenges.